Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Core Insights - Quoin Pharmaceuticals has released the fifth episode of the NETHERTON NOW video series, highlighting the social and emotional impact of Netherton Syndrome and the urgent need for an approved treatment [1][4] - The video features twin sisters Allie and Kaleigh Fasanella, who share their lifelong struggles with Netherton Syndrome, emphasizing the disease's unpredictable nature and its toll on their daily lives and mental health [2][3] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a commitment to addressing unmet medical needs [7] - The company is advancing its lead product candidate, QRX003, in pivotal clinical trials for the treatment of Netherton Syndrome, with early data showing encouraging improvements in key clinical outcomes [4][6] Product Information - QRX003 is a topical lotion designed to promote a normalized skin-shedding process and strengthen the skin barrier, addressing the symptoms of Netherton Syndrome [6] - The product is formulated with a proprietary delivery technology and is intended to be applied twice daily to the entire skin surface, excluding the scalp [6] Campaign and Awareness - The Netherton NOW campaign was initiated to increase awareness of Netherton Syndrome, and the positive reaction to the campaign has been significant since its launch over six months ago [4][5] - The personal stories shared by Allie and Kaleigh are aimed at building awareness of the challenges faced by patients and families living with Netherton Syndrome [4][3]